Literature DB >> 28051239

Ex vivo expansion of antigen-specific CD4+CD25+ regulatory T cells from autologous naïve CD4+ T cells of multiple sclerosis patients as a potential therapeutic approach.

Y-J Xiang1, M Ren, H Jiang, T-T Yang, Y He, D-H Ao, Y-Y Wang, Q Zhang, X-J He, X-G Gao, G-Z Liu.   

Abstract

OBJECTIVE: CD4+CD25+ regulatory T cells (Tregs) have been found to have a decreased effector function in patients with multiple sclerosis (MS). In this study, we co-cultured naïve CD4+ T cells of MS patients with myelin basic protein (MBP)85-99 peptide as specific antigen and allogenic B cells as antigen-presenting cells, in an attempt to generate adequate antigen-specific CD4+CD25+ Tregs with normal or improved immune function. PATIENTS AND METHODS: Naïve CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) from patients with MS (n=5) and healthy controls (HC, n=5). Furthermore, these purified naive CD4+ T cells were co-cultured with the CD40-activated B cells and MBP85-99 peptide to induce MBP-reactive CD4+CD25highCD127low Tregs. After harvesting these Tregs via a flow sorter, real-time PCR and mixed lymphocyte reaction (MLR) assay were performed to characterize cellular immune function. Supernatant interleukin (IL)-10 and transforming growth factor (TGF)-β1 protein levels were detected by an enzyme-linked immunosorbent assay (ELISA).
RESULTS: With this method, the frequency of CD4+CD25highCD127low Tregs in CD4+ T cells was 3.5%-6%. In both MS and HC groups, there were relatively lower proliferation indices (PI) of MLR assay but higher supernatant IL-10 and TGF-β1 levels in the presence of MBP than those in the presence of other control antigens, where no significant differences were found.
CONCLUSIONS: Via the ex vivo culture, adequate MBP-reactive CD4+CD25+ Tregsderived from autologous naïve CD4+ T cells of MS patients, were obtained and returned to normal without immune defects, and even upregulated their immunosuppressive function mostly through the elevated release of IL-10 and TGF-β1.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28051239

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Association between CD40 rs1883832 and immune-related diseases susceptibility: A meta-analysis.

Authors:  Jiaxuan Qin; Jinchun Xing; Rongfu Liu; Bin Chen; Yuedong Chen; Xuan Zhuang
Journal:  Oncotarget       Date:  2017-06-28

2.  The effects of TGF-β1 on staphylococcus epidermidis biofilm formation in a tree shrew biomaterial-centered infection model.

Authors:  Yujie Lei; Yushan Xu; Peng Jing; Bingquan Xiang; Keda Che; Junting Shen; Minjie Ning; Ying Chen; Yunchao Huang
Journal:  Ann Transl Med       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.